Previous 10 | Next 10 |
A look at the top 10 most actives in the United States Next.e.GO N.V. (EGOX) rose 38.0% to $0.0381 on volume of 59,468,925 shares Greenwave Technology Solutions Inc. (GWAV) rose 1.5% to $0.066 on volume of 45,683,331 shares Global Mofy Metaverse Limited (GMM) rose 68.4% to $1.5667 on volu...
– Preclinical data demonstrates the potential for improved treatment outcomes and reduced toxicity for patients with AML – – Data supports the design of Phase 1 clinical trial of SENTI-202 with patient dosing anticipated in the second quarter of 2024 – ...
– IND for SENTI-202, a potential first-in-class logic-gated treatment for AML, cleared by the U.S. FDA; First patient dosing anticipated in the second quarter of 2024 – – Cash and anticipated receivables from GeneFab transaction expected to fund operations into the ...
2024-01-05 16:15:54 ET More on Senti Biosciences Senti Biosciences GAAP EPS of -$0.77 misses by $0.33 Senti stock soars 175% on Chinese development deal for cancer drug Seeking Alpha’s Quant Rating on Senti Biosciences Historical earnings data for Sent...
– Strategic resource allocation to focus investment on clinical development of SENTI-202 and SENTI-301A partnership in China; interim data from Phase 1 clinical trial of SENTI-202 expected in 2H 2024 – – Anticipated cost savings, which includes an approximately 37% ...
2023-12-22 12:23:57 ET DENVER, Colo., Dec. 22, 2023 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual midday volume; Royalty Management Holding Corp (NASDAQ: RMCO), Senti Biosciences Inc (NASDAQ: SNTI), Polished.com Inc...
2023-12-22 09:51:52 ET DENVER, Colo., Dec. 22, 2023 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual volume; Royalty Management Holding Corp (NASDAQ: RMCO), Senti Biosciences Inc (NASDAQ: SNTI), Cidara Therapeutics Inc...
– First patient in Phase 1 clinical trial expected to be treated in Q2 2024 – – Initial clinical efficacy data expected by year-end 2024 and durability data expected in 2025 – – SENTI-202 is a potential first-in-class off-the-shelf CAR-NK cell ...
2023-11-14 02:32:14 ET More on Senti Biosciences Senti stock soars 175% on Chinese development deal for cancer drug Seeking Alpha’s Quant Rating on Senti Biosciences Historical earnings data for Senti Biosciences Financial information for Senti Bioscie...
– IND for SENTI-202, a potential first-in-class logic-gated treatment for cancer, on track for clearance in Q4 2023 – – Established new strategic collaboration with Celest Therapeutics for clinical development of SENTI-301A to treat liver cancer in China – ...
News, Short Squeeze, Breakout and More Instantly...
Trending Stock
5.74%Change Percent:
Senti Biosciences Inc. Company Name:
SNTI Stock Symbol:
NASDAQ Market:
Senti Biosciences Inc. Website:
A look at the top 10 most actives in the United States Zoomcar Holdings Inc. (ZCAR) rose 58.3% to $0.2162 on volume of 130,087,791 shares Maxeon Solar Technologies Ltd. (MAXN) rose 3.6% to $0.1863 on volume of 71,767,970 shares SMX (Security Matters) Public Limited Company (SMX) rose 17.1...
A look at the top 10 most actives in the United States Senti Biosciences Inc. (SNTI) rose 51.3% to $0.4175 on volume of 386,768,896 shares NVIDIA Corporation (NVDA) rose 0.6% to $124.3 on volume of 277,459,318 shares PROSHARES TRUST (SQQQ) fell 1.9% to $8.12 on volume of 139,088,335 share...
A look at the top 10 most actives in the United States Complete Solaria Inc Com (CSLR) rose 58.5% to $1.775 on volume of 71,457,263 shares Senti Biosciences Inc. (SNTI) rose 55.1% to $0.428 on volume of 64,207,396 shares Golden Heaven Group Holdings Ltd. (GDHG) rose 13.3% to $0.1711 on vo...